Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SNP Consortium's Next Focus Could Be Drug Safety, Bristol Exec Suggests

Executive Summary

The pharmaceutical industry SNP consortium's next focus should be on data that could help minimize side effects, Bristol-Myers Squibb Senior VP-Early Discovery & Applied Technology Elliot Sigal, MD/PhD, suggested.

You may also be interested in...



Rx Import Bill Prohibits Contracts To Prevent Return Shipments To U.S.

Drug manufacturers would not be able to use contracts with foreign distributors to prohibit reimportation of their products under the version of the prescription drug import amendments approved by the Agriculture Appropriations conference Oct. 5.

Bristol Rx Expansion Plans Include Biologics Manufacturing

Bristol plans to expand into biologics development and manufacturing as part of its "external development" plans for the pharmaceutical division following the divestments of Clairol and Zimmer.

Consortium Commits 10 Companies To Publicize SNP Results

The SNP Consortium unveiled April 15 with funding from the Wellcome Trust and 10 major pharmaceutical companies completes over a year of discussions between the academic, industrial and government research communities over commercialization of the genomic research tool and pre-empts a potential flashpoint for the drug industry.

UsernamePublicRestriction

Register

ID1129947

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel